Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP250883.RAuLIp2ZVqj1pDPf-T3UfhXEk10IajQH_9sGAEh9C2FG4130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP250883.RAuLIp2ZVqj1pDPf-T3UfhXEk10IajQH_9sGAEh9C2FG4130_provenance.
• NP554350.RAA7zbkqppvTMI_bfzQ40VDZwytBCcgauEAd0o9T_o0r0130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP554350.RAA7zbkqppvTMI_bfzQ40VDZwytBCcgauEAd0o9T_o0r0130_provenance.
• NP620934.RAfboSOBVTMfqJXPZ799hgX-1uzOWLL0MwhTtlm6LfSeU130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620934.RAfboSOBVTMfqJXPZ799hgX-1uzOWLL0MwhTtlm6LfSeU130_provenance.
• NP402465.RAurJNUpK4IDlX8-PR7voLNUG68h5CiwZJpd38XExLC4o130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP402465.RAurJNUpK4IDlX8-PR7voLNUG68h5CiwZJpd38XExLC4o130_provenance.
• NP852602.RAjcguNKsT1vFm8ztTiLOclL37A68l8h1vQd8Bp5pn5C8130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852602.RAjcguNKsT1vFm8ztTiLOclL37A68l8h1vQd8Bp5pn5C8130_provenance.
• NP623106.RARoA1KKIvSE1Ylxz3tBvcoCNcEaJEqctxtg5vrP4vzYw130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623106.RARoA1KKIvSE1Ylxz3tBvcoCNcEaJEqctxtg5vrP4vzYw130_provenance.
• NP625562.RATdaMA1JuGLlCdgflaebJh6wb0la8nbiSEck6l2VqfYE130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625562.RATdaMA1JuGLlCdgflaebJh6wb0la8nbiSEck6l2VqfYE130_provenance.
• NP621914.RA4nrUnoHcX7yz9c-fcT9F4o-Kn_WNk5ovl63GTc1uKms130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621914.RA4nrUnoHcX7yz9c-fcT9F4o-Kn_WNk5ovl63GTc1uKms130_provenance.
• NP572762.RA0DFxwYPvk0BODxfDuJbsnwhIoWgpuyjjlSgPCqmBJ0c130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572762.RA0DFxwYPvk0BODxfDuJbsnwhIoWgpuyjjlSgPCqmBJ0c130_provenance.
• NP572768.RA4f190-4K2azgUKvWrEhoLmNwJFym-TDe7dFFLQhyl0M130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572768.RA4f190-4K2azgUKvWrEhoLmNwJFym-TDe7dFFLQhyl0M130_provenance.
• NP624421.RAM46u9ZH9igAJdsQVq6WgUvjoGJbhpprzBXI9tnkWHMc130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624421.RAM46u9ZH9igAJdsQVq6WgUvjoGJbhpprzBXI9tnkWHMc130_provenance.
• assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP572763.RAHSmhtwWJmjqj90JWiCoRvIAyTMdshNS6HwNuEBvR_w0130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572763.RAHSmhtwWJmjqj90JWiCoRvIAyTMdshNS6HwNuEBvR_w0130_provenance.
• NP572764.RAvXMTkN3Tj4O85ihJiAo-AL-Epv6GgvBc8r7yWezEzAU130_assertion description "[Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572764.RAvXMTkN3Tj4O85ihJiAo-AL-Epv6GgvBc8r7yWezEzAU130_provenance.